title: Clinical practice in management of hydration for lung cancer patients receiving cisplatin-based chemotherapy in Japan: a questionnaire survey.
abstract: A questionnaire survey was performed to investigate the actual hydration methods used with cisplatin-containing regimens at various institutions in Japan to gain an overview of the varieties employed. Replies were received from 368 of 686 institutions board-certified by the Japanese Respiratory Society. In 233 institutions (63%), new lung cancer patients were treated regularly with regimens containing cisplatin at ≥60 mg/m2. In 172 institutions (48%), hydration with <3000 ml of intravenous saline was performed on day 1. In 225 institutions (65%), hydration was performed for up to 3 days at most, but no more than 48 (14%) of the institutions that responded did so on day 1 only. Two to three weeks of hospitalization was needed for the initial course at most institutions (76%). Thirteen institutions (4%) treated patients as outpatients after the second course, whereas none did so from the beginning of treatment. Despite inconsistencies among the methods used by the various institutions, 84% of those surveyed considered their approaches to be appropriate. Some useful objective indices for deciding the volume or duration of hydration are needed.
authors.affiliation: Division of Respirology, Neurology and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume City, Fukuoka 830-0011, Japan. kayamada@med.kurume-u.ac.jp
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Yamada
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Yoshida
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Zaizen
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Okayama
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Naito
authors.forename: Fumie
authors.initials: F
authors.lastname: Yamashita
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Takeoka
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Mizoguchi
authors.forename: Kazuko
authors.initials: K
authors.lastname: Yamada
authors.forename: Koichi
authors.initials: K
authors.lastname: Azuma
mesh_terms: D000230:Adenocarcinoma / Q000628:therapy*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005440:Fluid Therapy; D006801:Humans; D007564:Japan; D008175:Lung Neoplasms / Q000628:therapy*; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D011795:Surveys and Questionnaires
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin